凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06821 凯莱英

已收盘 09-29 16:08:04

159.800

+3.100

+1.98%

最高170.800	最低156.100	成交量128.78万
今开159.800	昨收156.700	日振幅9.38%
总市值578.48亿	流通市值44.48亿	总股本3.62亿
成交额2.10亿	换手率4.63%	流通股本2,783万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06821","market":"HK","secType":"STK","nameCN":"凯莱英","latestPrice":159.8,"timestamp":1790669284008,"preClose":156.7,"halted":0,"volume":1287840,"delay":0,"changeRate":0.01978302488832178,"floatShares":27834500,"shares":362000000,"eps":3.6966828288534264,"marketStatus":"已收盘","change":3.1,"latestTime":"09-29 16:08:04","open":159.8,"high":170.8,"low":156.1,"amount":210201921,"amplitude":0.09381,"askPrice":159.9,"askSize":1600,"bidPrice":159.8,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":3.421105652489447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790731800000},"marketStatusCode":5,"adr":0,"listingDate":1639065600000,"exchange":"SEHK","adjPreClose":156.7,"dividendRate":0.009499,"openAndCloseTimeList":[[1790645400000,1790654400000],[1790658000000,1790668800000]],"volumeRatio":2.097272,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"002821","market":"SZ","secType":"STK","nameCN":"凯莱英","latestPrice":179.12,"timestamp":1790665200000,"preClose":180.53,"halted":0,"volume":7552300,"delay":0,"premium":"-23.74"}},"requestUrl":"/m/hq/s/06821","defaultTab":"news","newsList":[{"id":"1197248244","title":"异动解读｜凯莱英盘中上涨3.13%，董事会通过章程修订议案叠加CRO行业高景气催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1197248244","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197248244?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:41","pubTimestamp":1790646072,"startTime":"0","endTime":"0","summary":"9月29日，凯莱英盘中上涨3.13%，报161.9港元，成交额977.28万港元。消息面上，公司9月28日召开第五届董事会第十五次会议，全票审议通过《公司章程》修订议案，因A股限制性股票激励计划首次授予的243.65万股限制性股票完成登记，注册资本由3.6066亿元增至3.6195亿元，并定于10月20日召开临时股东会审议。行业层面，CRO/CDMO板块持续受益于创新药高景气，叠加AI制药商业化加速及医药工业\"十五五\"规划政策催化，板块整体表现活跃。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"凯莱英盘中上涨，CRO高景气叠加章程修订","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253164","title":"凯莱英：关于召开2026年第四次临时股东会的通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253164","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670253164?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:47","pubTimestamp":1790603220,"startTime":"0","endTime":"0","summary":"证券日报网讯9月28日，凯莱英发布公告称，公司将于2026年10月20日召开2026年第四次临时股东会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885502414.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885502414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06821","BK0239","BK1191","LU1328615791.USD","BK0132","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670258412","title":"凯莱英：第五届董事会第十五次会议决议的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2670258412","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670258412?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:27","pubTimestamp":1790602020,"startTime":"0","endTime":"0","summary":"证券日报网讯9月28日，凯莱英发布公告称，公司于2026年9月28日召开第五届董事会第十五次会议，审议通过《关于修订〈凯莱英医药集团（天津）股份有限公司章程〉的议案》《关于提请召开2026年第四次临时股东会的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885450982.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885450982.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["002821","BK1191","06821","BK0132","BK0239","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122081743","title":"凯莱英(06821)拟修订章程　注册资本由3.6066亿股增至3.6195亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1122081743","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122081743?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:46","pubTimestamp":1790599599,"startTime":"0","endTime":"0","summary":"本报讯　凯莱英医药集团（天津）股份有限公司9月28日在港交所发布海外监管公告称，公司第五届董事会第十五次会议已审议通过《关于修订<凯莱英医药集团（天津）股份有限公司章程>的议案》，拟就注册资本及股本结构等条款进行调整，并将提交股东大会审议。根据公司2026年A股限制性股票激励计划首次授予的2,436,500股限制性股票完成登记情况，其中1,285,200股为新增股份，1,151,300股来自2024年回购股份。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151096834","title":"凯莱英（06821）发布海外监管公告：拟于10月20日召开2026年第四次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=1151096834","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151096834?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:46","pubTimestamp":1790599576,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司9月28日在港交所披露海外监管公告称，公司将于2026年10月20日14:00在天津经济技术开发区第七大街71号公司会议室召开2026年第四次临时股东大会，会议采取现场表决与网络投票相结合的方式进行。公司提醒，出席会议的股东交通及食宿费用自理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153727516","title":"凯莱英医药集团（06821）董事会通过章程修订议案 拟将注册资本增至361,948,670元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153727516","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153727516?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:36","pubTimestamp":1790598968,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司9月30日公告称，公司已于2026年9月28日以通讯方式召开第五届董事会第十五次会议。会议通知于2026年9月22日发出，公司9名董事全部出席，会议的召开符合相关法律法规及《公司章程》规定。一是《关于修订<凯莱英医药集团（天津）股份有限公司章程>的议案》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136615674","title":"凯莱英（06821）将于10月20日召开2026年第四次临时股东大会","url":"https://stock-news.laohu8.com/highlight/detail?id=1136615674","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136615674?lang=zh_cn&edition=full","pubTime":"2026-09-28 20:25","pubTimestamp":1790598332,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司9月29日发布公告称，公司拟于2026年10月20日（星期二）14时在中国天津市经济技术开发区第七大街71号召开2026年第四次临时股东大会。会议拟审议的特别决议案为“建议修订公司章程”。公司将于2026年10月14日（星期三）至2026年10月20日（星期二）暂停办理H股股份过户登记。公司提示，2026年10月19日并非香港工作日，届时办公处不接受现场递交文件。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159597572","title":"凯莱英：摩根大通减持，好仓比例降至8.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159597572","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159597572?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:32","pubTimestamp":1790587936,"startTime":"0","endTime":"0","summary":"根据信息披露，摩根大通于2026年9月23日以每股均价159.1287港元场外卖出凯莱英H股8.32万股，涉资约1324.16万港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次减持前持有凯莱英好仓253.36万股，占比9.1%；减持后持股量为245.04万股，好仓比例降至8.8%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128255083","title":"凯莱英：摩根大通增持，好仓比例升至9.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128255083","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128255083?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:31","pubTimestamp":1790587918,"startTime":"0","endTime":"0","summary":"摩根大通于2026年9月22日以每股均价160.8185港元场外买入41.98万股凯莱英（06821）H股，涉资约6751.16万港元。该笔为场外交易（代价性质：现金），未经联交所公开市场撮合，不属二级市场直接买卖。摩根大通此次增持前持有凯莱英好仓211.38万股，占比7.59%；增持后持股量为253.36万股，好仓比例升至9.1%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670940718","title":"凯莱英（002821）9月24日主力资金净卖出3.00亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670940718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670940718?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:21","pubTimestamp":1790558508,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，凯莱英报收于178.3元，下跌5.16%，换手率2.55%，成交量8.1万手，成交额14.78亿元。近5日资金流向一览见下表：凯莱英融资融券信息显示，融资方面，当日融资买入7837.51万元，融资偿还1.29亿元，融资净偿还5018.17万元。凯莱英主营业务：全球制药工艺的技术创新和商业化应用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800002873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","06821","002821","BK1191","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670240587","title":"Schroders PLC减持凯莱英(06821)17.58万股 每股作价约150.23港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670240587","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670240587?lang=zh_cn&edition=full","pubTime":"2026-09-27 18:51","pubTimestamp":1790506317,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，9月24日，Schroders PLC减持凯莱英(06821)17.58万股，每股作价150.2338港元，总金额约为2641.11万港元。减持后最新持股数目为268.64万股，最新持股比例为9.65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1191","06821","EWH","BK0132","LU1328615791.USD","002821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670438574","title":"创新药龙头大涨超9%，股价盘中创历史新高，年内涨超260%；艾美疫苗涨超6%，凯莱英涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670438574","media":"中新经纬","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670438574?lang=zh_cn&edition=full","pubTime":"2026-09-25 14:15","pubTimestamp":1790316900,"startTime":"0","endTime":"0","summary":"25日午后，港股医药生物板块逆市上涨。个股方面，艾美疫苗涨超6%，凯莱英涨超4%，康诺希生物、药明生物、药明康德等涨超2%。其中，创新药龙头金斯瑞生物科技，盘中股价创历史新高。截至发稿，报43.480港元/股，涨9.41%，股价较年初涨超260%，市值989.28亿港元。公开资料显示，金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609253884268840.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609253884268840.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0132","BK1574","MEDX","LNGR","BK0239","159992","06978","IBBQ","002821","06660","LU1328615791.USD","06821","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182059758","title":"异动解读｜凯莱英盘中上涨3.21%，前日限售股上市叠加机构密集减持致超跌后盘面修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1182059758","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182059758?lang=zh_cn&edition=full","pubTime":"2026-09-25 11:12","pubTimestamp":1790305936,"startTime":"0","endTime":"0","summary":"9月25日，凯莱英盘中上涨3.21%，报154.5港元，成交额1106.42万港元。消息面上，公司前一交易日因A股限制性股票激励计划首批128.52万股授予股份上市，叠加Schroders PLC以每股约155.66港元减持18.84万股、此前摩根大通及高管洪亮相继减持，多重抛压致股价下跌3.37%至152.0港元。经获利回吐压力集中释放后，股价呈现技术性修复。凯莱英是一家主要从事医药外包一站式综合服务的公司，业务涵盖小分子CDMO、化学大分子CDMO、生物大分子CDMO、制剂CDMO及临床研究服务等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"凯莱英超跌后反弹，订单增长叠加FDA进展","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669493732","title":"Schroders PLC减持凯莱英(06821.HK)18.84万股 每股作价约155.66港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669493732","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669493732?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:53","pubTimestamp":1790254421,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06821","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161144410","title":"凯莱英(06821)完成2026年A股限制性股票激励计划首批回购股份登记","url":"https://stock-news.laohu8.com/highlight/detail?id=1161144410","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161144410?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:41","pubTimestamp":1790250088,"startTime":"0","endTime":"0","summary":"2026年9月24日，凯莱英医药集团（天津）股份有限公司公告称，已在中国证券登记结算有限责任公司深圳分公司完成2026年A股限制性股票激励计划首次授予部分的股份登记。股本结构方面，授予后公司总股本维持361,948,670股不变，仅在结构上将1,151,300股由无限售条件流通股转为有限售条件流通股。截至本公告披露日，公司回购专用证券账户已无剩余股份；2024年3月7日至2026年2月18日期间，公司通过集中竞价方式累计回购12,300,701股，支付总金额约10.00亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154802181","title":"凯莱英：Schroders PLC减持，好仓比例降至10.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154802181","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154802181?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:32","pubTimestamp":1790242347,"startTime":"0","endTime":"0","summary":"Schroders PLC于2026年9月21日在联交所场内以每股均价155.6581港元卖出凯莱英（06821）H股股份18.84万股，涉资约2932.60万港元，属场内主动交易，即在二级市场直接买卖股份。Schroders PLC此次减持前持有凯莱英好仓320.83万股，占比11.53%；减持后持股量为301.99万股，好仓比例降至10.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120085661","title":"异动解读｜凯莱英盘中下跌3.37%，限制性股票激励首批授予股份当日上市叠加机构高管密集减持","url":"https://stock-news.laohu8.com/highlight/detail?id=1120085661","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120085661?lang=zh_cn&edition=full","pubTime":"2026-09-24 09:31","pubTimestamp":1790213486,"startTime":"0","endTime":"0","summary":"9月24日，凯莱英盘中下跌3.37%，报152.0港元，成交额381.23万港元。消息面上，公司9月23日公告，A股限制性股票激励计划首次授予部分128.52万股已完成登记，于9月24日上市，授予对象462人。此外，公司此前短期累计涨幅显著，摩根大通、南方基金及高管洪亮近期相继减持，获利回吐压力持续释放，多重因素叠加对市场情绪形成压制。凯莱英是一家主要从事医药外包一站式综合服务的公司，业务涵盖小分子CDMO、化学大分子CDMO、生物大分子CDMO、制剂CDMO及临床研究服务等。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"凯莱英盘中走低，激励股上市叠加减持压力","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182294967","title":"凯莱英(06821)完成2026年A股限制性股票激励计划首批授予登记 1.29百万股9月24日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1182294967","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182294967?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:22","pubTimestamp":1790166126,"startTime":"0","endTime":"0","summary":"凯莱英医药集团（天津）股份有限公司9月24日公告称，公司2026年A股限制性股票激励计划首次授予部分的股票登记工作已完成。此次向462名激励对象定向发行1,285,200股人民币A股普通股，占授予前公司A股股本总额332,828,960股的0.3861%，占授予前A+H股总股本360,663,470股的0.3563%。上述股份将于2026年9月24日上市，性质为有限售条件股份。激励计划有效期最长不超过72个月。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173569177","title":"异动解读｜凯莱英盘中上涨3.01%，化学大分子基地顺利通过美国FDA批准前检查提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1173569177","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173569177?lang=zh_cn&edition=full","pubTime":"2026-09-22 10:33","pubTimestamp":1790044392,"startTime":"0","endTime":"0","summary":"9月22日，凯莱英盘中上涨3.01%，报164.4港元，成交额6594.21万港元。消息面上，公司于9月21日披露其化学大分子基地生产的某原料药项目已于6月底至7月初完成美国FDA批准前检查，并于8月底收到FDA签发的工厂检查报告，标志着公司合规能力再获国际监管认可。此前公司股价因短期快速拉升后获利回吐一度回调，FDA检查利好落地叠加基本面支撑，推动股价企稳反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"凯莱英上涨，FDA检查通过提振信心","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669151594","title":"【纪实】凯莱英化学大分子基地顺利通过美国FDA批准前检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2669151594","media":"同花顺","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669151594?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:05","pubTimestamp":1789981500,"startTime":"0","endTime":"0","summary":"凯莱英化学大分子基地生产的某原料药项目，于2026年6月底至7月初完成了美国食品药品监督管理局(FDA)的批准前检查(PAI)，并于8月底收到FDA签发的工厂检查报告(EIR)，标志着公司合规能力再次 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260921/c680129684.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260921/c680129684.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["002821","BK1191","BK0132","BK0239","BK4588","LABU","06821","LU1328615791.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.asymchem.com","stockEarnings":[{"period":"1week","weight":-0.0182},{"period":"1month","weight":0.2242},{"period":"3month","weight":0.4403},{"period":"6month","weight":0.55},{"period":"1year","weight":0.712},{"period":"ytd","weight":1.2313}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"凯莱英医药集团（天津）股份有限公司是一家主要从事提供医药外包一站式综合服务的中国公司。该公司的业务包括小分子药物定制研发生产（CDMO）、化学大分子CDMO、临床研究服务、制剂CDMO、生物大分子CDMO、技术输出和合成生物技术。该公司的产品类别涵盖多肽、寡核苷酸、单克隆抗体、抗体偶联药物和信使RNA等。该公司主要在国内外市场开展其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.058449},{"month":2,"riseRate":0.4,"avgChangeRate":0.006895},{"month":3,"riseRate":0.4,"avgChangeRate":0.004398},{"month":4,"riseRate":0.6,"avgChangeRate":-0.036171},{"month":5,"riseRate":0.4,"avgChangeRate":0.006805},{"month":6,"riseRate":0.6,"avgChangeRate":0.053806},{"month":7,"riseRate":0.6,"avgChangeRate":0.056483},{"month":8,"riseRate":0.4,"avgChangeRate":-0.032767},{"month":9,"riseRate":0.8,"avgChangeRate":0.188301},{"month":10,"riseRate":0,"avgChangeRate":-0.125552},{"month":11,"riseRate":0.5,"avgChangeRate":0.010601},{"month":12,"riseRate":0.25,"avgChangeRate":-0.010173}],"exchange":"SEHK","name":"凯莱英","nameEN":"ASYMCHEM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯莱英,06821,凯莱英股票,凯莱英股票老虎,凯莱英股票老虎国际,凯莱英行情,凯莱英股票行情,凯莱英股价,凯莱英股市,凯莱英股票价格,凯莱英股票交易,凯莱英股票购买,凯莱英股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯莱英(06821)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯莱英(06821)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}